Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 270 Results

December 9, 2024

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

December 4, 2024

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

November 19, 2024

Relmada Therapeutics to Present at Jefferies London Healthcare Conference

November 14, 2024

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

November 7, 2024

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 4, 2024

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

August 7, 2024

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

August 5, 2024

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

June 18, 2024

Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry

June 10, 2024

Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

«...3 456 7 8...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top